bluebird bio
BLUE
$0.96
Share price
-4.04%
Change (1 day)
-74.81%
Change (1 year)
bluebird bio (BLUE) - Total debt
Total debt on the balance sheet as of September 2023 : $0.30 B
According to bluebird bio 's latest financial reports the company's total debt is $0.30 B. A company’s total debt is the sum of all current and non-current debts.
bluebird bio - Total debt on balance sheet (from 2015 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $0.28 B | 214.11% |
| 2021-12-31 | $89.58 M | 36.94% |
| 2020-12-31 | $65.41 M | -65.75% |
| 2019-12-31 | $0.19 B | 23.42% |
| 2018-12-31 | $0.15 B | -0.68% |
| 2017-12-31 | $0.15 B | 29.68% |
| 2016-12-31 | $0.12 B | 94.08% |
| 2015-12-31 | $61.9 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $20.36 B | 6,606.17% | 🇫🇷 France |
 Merck MRK | $34.21 B | 11,167.11% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $30.81 M | -89.85% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 GlycoMimetics
GLYC | $0.63 M | -99.79% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.09 B | 261.05% | 🇺🇸 USA |